MIRA Pharmaceuticals, Inc. is a clinical development stage biopharmaceutical company. The company is headquartered in Baltimore, Maryland.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -184.30% |
| Return on Assets | -112.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.22 |
| Price-to-Book | 4.46 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.45 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $42.02M |
| Float | $35.03M |
| % Insiders | 16.71% |
| % Institutions | 5.03% |
Volatility is currently contracting